DivGro is now DivGro 2.0!

DivGro moved to another platform and is now DivGro 2.0!

Please enjoy complimentary access to all the content on DivGro 2.0 until I formally launch it! You can sign up for free and join more than 1,250 existing members!

Complimentary access includes my monthly newsletter and articles like
 How to Assess Dividend Quality and The Chowder Ruleand a live spreadsheet of my DivGro Portfolio.

Read more About DivGro 2.0 ...

Friday, November 27, 2015

Recent Buy: HCP Inc.

This article originally appeared on The DIV-Net on Friday, 27 November 2015.

6 Nov 2015: Bought 75 shares of HCP at $34.00 per share.

Formed in 1985 and based in Irvine, California, HCP, Inc (NYSE:HCP) is an independent hybrid REIT (real estate investment trust). The company invests primarily in properties serving the healthcare industry in the United States, including sectors such as senior housing, life science, medical office, hospital and skilled nursing. HCP acquires, develops, leases, manages and disposes of healthcare real estate and provides financing to healthcare providers.

HCP is a Dividend Champion with an impressive track record of 30 consecutive years of dividend increases. The company pays quarterly dividends of 56.5¢ per share in the months of February, May, August and November.

My buy price of $34.00 results in an initial yield on cost (YoC) of 6.65%. Adding 75 shares of HCP increases DivGro's projected annual dividend income by $169.50 to a total of $6,850.

The company's 10-year price history is shown in the following chart, along with my buy price. The stock outperformed the S&P 500 by more than 50% through May 2013. Since then, the stock has lost ground, dropping about 38% from its all time high closing price of $55.28 on 21 May 2013. Overall, HCP has underperformed the S&P 500 by nearly 50% in the last decade.

Source: Scottrade

Of course, HCP is a dividend paying stock, so the picture looks much better if we include dividends. According to longrundata.com, an investment in HCP 10 years ago would have returned 8.94% on an annualized basis. An investment of $1,000 in HCP 25 years ago would be worth $23,558 now, for an annualized return of 13.46%.


As mentioned earlier, HCP has a track record of 30 consecutive years of dividend increases. The company is the only REIT included in the S&P 500 Dividend Aristocrats Index. The dividend of $2.26 per year is a yield of almost 7%, which is a 5-year high for the company:

Source: Dividend.com

The following table presents HCP's dividend growth rates according to data available at tessellation.com. The data represent dividend growth rates through the end of 2014:

HCP Dividend Compound Annual Growth Rate

The current quarterly dividend of 56.5¢ per share represents a 3.67% increase over the 2014 dividend. Following is a chart showing the last 25 years of (split-adjusted) dividend payments:

The company's track record of dividend payments and dividend growth is impressive, but the question is, how sustainable is it? For REITs, a widely used metric to gauge performance is funds from operations (or FFO), which is obtained after adding depreciation and amortizations and other non-cash expenses to net income. Here is a chart of the per share AFFO (adjusted FFO) and FAD (funds available for distribution) in relation to the total annual dividend:

Data source: 2014 HCP Annual Report

The most recent dividend ratio (Dividend/AFFO) is 71.75%, which is a little high but still acceptable.


Given HCP current annual dividend of $2.26, we can use a dividend discount model (DDM) analysis to determine the fair value per share. DDM analysis is a variation of discounted cash flow analysis with dividends and dividend growth rate substituting for cash flow and growth rate.

Using a 9% discount rate, expected dividend growth at 3.5% for 3 years and 3% per year thereafter, HCP's fair value is $45.96 per share. For comparison, Morningstar's fair value is $53 and S&P Capital IQ has a 12-month target price of $43.

My buy price of $34 implies a discount to fair value of at least 25%. The following table provides some key statistics for HCP, with highlighted values relating to my selection criteria. Data sources include the CCC spreadsheet, Finviz, and Gurufocus.

HCP passes the following of my selection criteria:
  • Dividend streak: at least 5 consecutive years of dividend increases (30 years)
  • Dividend yield: at least 4.5% for REITs (6.65%)
  • Equity valuation multiple: price to funds from operations (FFO) is less than 16 (10.79x)
  • Dividend payout ratio: ratio of dividend to FFO per share is less that 75% (71.75%)
  • Fair value: price discount is at least 5% of fair value estimate (25%)
HCP fails the following of my selection criteria:
  • Dividend growth rate: 5-year DGR is at least 7.5% (3.45%)
  • Debt ratio: debt to market capitalization ratio is below 50% (109.61%)
Based on these statistics, HCP earns 5 out of a possible 7 stars: (*****--)


MorningStar Rating (*****)
Zacks Rank 3-Hold (D•D•A)† 
S&P Capital IQ's Stock Report (***--) Hold
Thomson Reuters StockReport+   (4/10) Neutral
TheStreet Ratings Rating Hold [C+]
The Motley Fool's CAPS Rating  (*****)
Dividend.com's DARS Rating  3.2/5


HCP is attractive for more reasons that its high yield and impressive dividend track record.

Standard and Poor's Rating Services recently affirmed its BBB+ corporate credit rating on HCP, stating that "HCP's financial risk is characterized by strong debt coverage measures and relatively low leverage".

Furthermore, the company will continue to benefit from favorable trends as an aging population requires housing and skilled nursing. Census figures indicate that more than 20% of US residents will be over the age of 65 by 2030, which is a potential major tailwind for HCP.

HCP's fundamentals are improving, too. On 2 November, HCP announced results for Q3-2015. Adjusted FFO increased by 5% to 79¢ compared to the year-ago quarter. The company increased full year per share guidance for adjusted FFO to $3.12-$3.18 per share.

One risk is continued uncertainty over HCR ManorCare, HCP's largest tenant, and its financial difficulties following legal issues. The troubled tenant accounts for about 32% of HCP's net operating income. Also, as is the case with most REITs, HCP's share price is sensitive to interest rate changes.

Other risks include the likelihood of health-care inflation and increased regulation of the health care industry, which could adversely impact HCP's tenants and their ability to afford rent.

Brad Thomas of iREIT Investor considers HCP a strong buy with a relatively safe dividend, although he believes Ventas Inc (NYSE:VTR) is the best healthcare REIT to buy right now. Other bloggers that recently bought shares of HCP include Dividend Diplomats, Dividend Hawk, My Dividend Pipeline, and American Dividend Dream.


  1. Nice addition with HCP. This month I have been on a health REIT kick adding to my HCP, HCN and VTR the first couple of weeks of November. All look attractive even though they have bounced back from their lows a couple weeks ago. I'm way long on the whole health REIT sector. Thanks for sharing.

    1. Hi DivHut -- good to hear from you. Those healthcare REIT's seem like excellent additions. I'm a little heavy on REITs now, so I'll probably focus on other sectors for the time being, but it is always welcome when readers share their buys or ideas for buys. Take care!

  2. I also recently added HCP. Great minds think alike perhaps? I sure hope so! I'm looking at VTR as my next REIT, just hoping that it will continue to stay depressed for a while.

    1. I really like HCP -- we'll see how it fares if/when interest rates are increased. I think the stock should be fine, and if it dips I'll buy more!


Please don't include links in comments. I will mark such comments as spam and the comment won't be published. To make me aware of your blog or website, comment on my Blogrole page instead.

Subscribe to Portfolio Insight and Save!

Use my affiliate link to sign up for a free 14-day, no-obligation trial of Portfolio Insight. No credit card required. If you decide to subscribe during the trial period, you'll receive a 20% discount on the first year's annual subscription price of $330. Please note the 20% affiliate discount does not apply to the monthly rate.